MDxHealth, Inc. Receives 2011 European Molecular Diagnostics for Oncology Technology Leadership Award
1/9/2012 6:10:30 AM
IRVINE, Calif. & LIEGE, Belgium--(BUSINESS WIRE)--Regulatory News:
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, announced today the receipt of the Frost & Sullivan 2011 European Molecular Diagnostics for Oncology Technology Leadership award. In giving the awards, Frost & Sullivan recognizes the strength and broad applicability of MDxHealth’s epigenetic technology platform in generating advanced tests for cancer assessment and the personalized treatment of patients.
comments powered by